drugset / Trial / NCT00546494

Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission

NCT00546494

Phase 4 Completed 350 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to determine the utility of Effexor® (venlafaxine) in achieving response, including time to response, maintaining remission, and time to remission as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D) and to determine the utility of Effexor® (venlafxine) on the various cluster of symptom scales in the 17-item HAM-D.

Timeline

Start
2004-02
Primary completion
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Venlafaxine Small molecule

Indications